Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2016

Published: Jul, 2016 | Pages: 77 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Review, H2 2016', provides in depth analysis on Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted pipeline therapeutics. 

The report provides comprehensive information on the Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)
- The report reviews Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) Overview 8
Therapeutics Development 9
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Products under Development by Stage of Development 9
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Products under Development by Therapy Area 10
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Products under Development by Indication 11
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Pipeline Products Glance 13
Late Stage Products 13
Early Stage Products 14
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Products under Development by Companies 15
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Products under Development by Universities/Institutes 18
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Therapeutics Assessment 20
Assessment by Monotherapy/Combination Products 20
Assessment by Mechanism of Action 21
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Companies Involved in Therapeutics Development 27
Aptose Biosciences Inc. 27
Conatus Pharmaceuticals Inc. 28
LG Life Science LTD. 29
New World Laboratories, Inc. 30
Novelix Pharmaceuticals, Inc. 31
Pharmedartis GmbH 32
Shire Plc 33
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Drug Profiles 34
BaxB-01 - Drug Profile 34
Product Description 34
Mechanism Of Action 34
R&D Progress 34
BaxG-03 - Drug Profile 35
Product Description 35
Mechanism Of Action 35
R&D Progress 35
BaxM-159 - Drug Profile 36
Product Description 36
Mechanism Of Action 36
R&D Progress 36
emricasan - Drug Profile 37
Product Description 37
Mechanism Of Action 37
R&D Progress 37
flavokawain A - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Granzyme B/VEGF - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
HaA-4 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
nivocasan - Drug Profile 46
Product Description 46
Mechanism Of Action 46
R&D Progress 46
NVX-207 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
NWL-53 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
plinabulin - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
Recombinant Protein to Activate CASP3 and CASP9 for Oncology - Drug Profile 53
Product Description 53
Mechanism Of Action 53
R&D Progress 53
Small Molecule to Activate Caspase-3 for Oncology - Drug Profile 54
Product Description 54
Mechanism Of Action 54
R&D Progress 54
Small Molecules to Activate Caspase 3 for Oncology - Drug Profile 55
Product Description 55
Mechanism Of Action 55
R&D Progress 55
Small Molecules to Inhibit Caspase 3 and Caspase 6 for Huntington's Disease - Drug Profile 56
Product Description 56
Mechanism Of Action 56
R&D Progress 56
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Dormant Projects 57
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Discontinued Products 62
Caspase 3 (Apopain or Cysteine Protease CPP32 or Protein Yama or SREBP Cleavage Activity 1 or CASP3 or EC 3.4.22.56) - Featured News & Press Releases 63
Jun 28, 2016: BeyondSprings Global Phase III Non-Small Cell Lung Cancer Clinical Trial for Plinabulin Launches in China 63
May 26, 2016: American Society of Clinical Oncology Selects BeyondSpring Abstract on Neutropenia Mitigation with Plinabulin Use for Publication 63
May 12, 2016: BeyondSpring Chief Medical Officer Served as Panelist at NewYorkBIO 64
May 04, 2016: Conatus Extends Positive Results with Emricasan in Phase 2 Liver Cirrhosis Clinical Trial 65
Apr 18, 2016: Conatus Late Breaker Oral Presentation at EASL Details Phase 2 Liver Cirrhosis Trial Three-month Data 67
Mar 30, 2016: Conatus Pharmaceuticals Announces Late Breaker Oral Presentation on Emricasan at EASL Meeting 68
Feb 24, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin at 4th Annual Cancer Biopartnering & Investment Forum in NYC 68
Feb 08, 2016: BeyondSpring Pharmaceuticals' Data Indicating Plinabulin Enhances Immune Response Provides Basis for Planned Phase I/II Combination Trial in NSCLC 68
Feb 03, 2016: FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis 69
Jan 11, 2016: Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis 70
Jan 07, 2016: BeyondSpring Pharmaceuticals to Present at 8th Annual Biotech Showcase 71
Jan 05, 2016: Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial 71
Jan 05, 2016: BeyondSpring Pharmaceuticals to Present Plinabulin-Immune System Interactions at AACR's 2016 Tumor Microenvironment Special Conference 73
Dec 21, 2015: BeyondSpring Pharmaceuticals Granted CTA by CFDA to initiate China Arm of Global Phase III Trial of Lead Asset Plinabulin 74
Nov 17, 2015: BeyondSpring Data Demonstrating Activity of Plinabulin in Kras-Mutant Tumors Presented at AACR-NCI-EORTC International Conference 2015 75
Appendix 76
Methodology 76
Coverage 76
Secondary Research 76
Primary Research 76
Expert Panel Validation 76
Contact Us 76
Disclaimer 77

List of Tables

Number of Products under Development for, H2 2016 9
Number of Products under Development by Therapy Area, H2 2016 10
Number of Products under Development by Indication, H2 2016 11
Comparative Analysis by Late Stage Development, H2 2016 13
Comparative Analysis by Early Stage Products, H2 2016 14
Number of Products under Development by Companies, H2 2016 15
Products under Development by Companies, H2 2016 16
Products under Development by Companies, H2 2016 (Contd..1) 17
Number of Products under Investigation by Universities/Institutes, H2 2016 18
Products under Investigation by Universities/Institutes, H2 2016 19
Assessment by Monotherapy/Combination Products, H2 2016 20
Number of Products by Stage and Mechanism of Action, H2 2016 22
Number of Products by Stage and Route of Administration, H2 2016 24
Number of Products by Stage and Molecule Type, H2 2016 26
Pipeline by Aptose Biosciences Inc., H2 2016 27
Pipeline by Conatus Pharmaceuticals Inc., H2 2016 28
Pipeline by LG Life Science LTD., H2 2016 29
Pipeline by New World Laboratories, Inc., H2 2016 30
Pipeline by Novelix Pharmaceuticals, Inc., H2 2016 31
Pipeline by Pharmedartis GmbH, H2 2016 32
Pipeline by Shire Plc, H2 2016 33
Dormant Projects, H2 2016 57
Dormant Projects (Contd..1), H2 2016 58
Dormant Projects (Contd..2), H2 2016 59
Dormant Projects (Contd..3), H2 2016 60
Dormant Projects (Contd..4), H2 2016 61
Discontinued Products, H2 2016 62